Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | IDUA | P35475 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3668608 | 0.98 | MEN1 (0.32) | MEN1CYP1A2KMT2ASMN1; SMN2TSHR | |
| SCHEMBL13879970 | 0.91 | — | — | |
| SCHEMBL3973511 | 0.78 | — | — | |
| Hydrochloric Acid SCHEMBL3675114 | 0.77 | PNP (0.30) | — | |
| SCHEMBL14345875 | 0.76 | SPHK2 (0.33) | — | |
| SCHEMBL13880002 | 0.71 | — | — | |
| SCHEMBL5680169 | 0.68 | CA12 (0.32) | — | |
| SCHEMBL3079040 | 0.68 | CYP1A2 (0.48) | MEN1CYP1A2KMT2ASMN1; SMN2TSHR | |
| SCHEMBL30428351 | 0.68 | CA1 (0.42) | MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL4762965 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090110720-A1 | Use of compounds for the prevention of drug-induced cell toxicity | RECEPTICON APS (DK) | 2009-04-30 | — | — | US | disclosed |
| US-20090098145-A1 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | SIRION THERAPEUTICS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2007150046-A2 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | SIRION THERAPEUTICS, INC (US) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090110720-A1 | Use of compounds for the prevention of drug-induced cell toxicity | SLC47A1, SLC10A6, SLC47A2 | MEN1 1662/4885CYP1A2 1917/4885KMT2A 4551/4885 |
| US-20090098145-A1 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | ALDH1A2, PDE6C, EYA2 | MEN1 1789/4885CYP1A2 4529/4885KMT2A 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.